12 medical centers form brain tumor research collaborative

March 22, 2020
Twelve institutions across the United States and Canada formed a collaborative designed to
In the Journals

Sharp declines in melanoma mortality 'unprecedented in cancer medicine'

March 19, 2020
The introduction and approval of new treatments for metastatic melanoma has led to significant declines in population-level mortality over the past…
FDA News

FDA grants anti-BCMA CAR-T orphan drug designation for advanced multiple myeloma

March 19, 2020
The FDA granted orphan drug designation to CART-ddBCMA, a chimeric antigen receptor T-cell therapy, for the treatment of multiple myeloma, according…
In the Journals

Anti-PD-1 therapy induces durable long-term responses in advanced melanoma

March 19, 2020
About three-quarters of patients with advanced melanoma who achieved complete responses to single-agent anti-PD-1 therapy remained in remission at 3…

Durvalumab plus chemotherapy, without tremelimumab, extends OS in small cell lung cancer

March 17, 2020
The addition of durvalumab to a choice of standard-of-care first-line chemotherapies conferred a sustained OS benefit for patients with…
FDA News

Phase 3 trial for locally advanced head and neck cancer terminated

March 13, 2020
A randomized phase 3 study designed to evaluate the addition of avelumab to chemoradiotherapy for patients with untreated locally advanced head and…
FDA News

FDA grants fast track designation to combination for advanced cervical cancer

March 13, 2020
The FDA granted fast track designation to balstilimab in combination with zalifrelimab for the treatment of women with relapsed or refractory…
FDA News

FDA approves Opdivo-Yervoy combination for previously treated hepatocellular carcinoma

March 11, 2020
The FDA granted accelerated approval to nivolumab plus ipilimumab for treatment of patients with hepatocellular carcinoma who previously received…
Meeting NewsPerspective

Lisocabtagene maraleucel active, safe, ‘worth considering’ in outpatient setting for lymphoma subset

March 10, 2020
ORLANDO — Nearly three-quarters of a cohort of patients with relapsed or refractory large B-cell lymphoma responded to treatment with…
Meeting News

Enfortumab vedotin plus pembrolizumab induces durable responses in metastatic urothelial carcinoma

HemOnc Today, March 10, 2020
The combination of enfortumab vedotin and pembrolizumab conferred high rates of durable responses among cisplatin-ineligible patients with metastatic…